Literature DB >> 12813618

Primary cardiac sarcoma involving the pulmonary artery and valve.

Richard D Bloomberg1, Jagdish W Butany, R J Cusimano, Richard L Leask.   

Abstract

Primary pulmonary artery neoplasms are rare and lethal. Those involving the pulmonary valve are even rarer with only a few reported cases in the literature. The poor prognosis of these neoplasms, despite attempted multimodal therapy, is largely related to delay and difficulty in diagnosis. The case of a 53-year-old woman is described who within one month of suddenly developing shortness of breath was found to have a mass arising from the pulmonary valve and extending through the pulmonary vasculature, requiring extensive surgical resection. She died two weeks postoperatively. The morphological findings of this primary pulmonary artery sarcoma are presented. Diagnosis, treatment, prognosis and literature are reviewed, and consideration of this tumour in the differential diagnosis of other pulmonary diseases is emphasized.

Entities:  

Mesh:

Year:  2003        PMID: 12813618

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  3 in total

1.  Surgical treatment for recurrent pulmonary artery sarcoma.

Authors:  Atsushi Omura; Satoshi Tobe; Kazunori Yoshida; Masahiro Yamaguchi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2008-01-22

2.  Clinicopathological and immunohistochemical features of pulmonary artery sarcoma: A report of three cases and review of the literature.

Authors:  Dong Chen; Guangfa Zhu; Dijia Wang; Zhe Zhang; Wei Fang; Zheng Qu
Journal:  Oncol Lett       Date:  2016-03-08       Impact factor: 2.967

3.  The role of matrix metalloproteinase in the intimal sarcoma-like cells derived from endarterectomized tissues from a chronic thromboembolic pulmonary hypertension patient.

Authors:  Takayuki Jujo; Seiichiro Sakao; Masanori Tsukahara; Masashi Kantake; Seiji Kantake; Miki Maruoka; Nobuhiro Tanabe; Masahisa Masuda; Koichiro Tatsumi
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.